<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-verified-clinical-benefit-non-malignant-neurological-accelerated-approvals-2026</loc>
    <lastmod>2026-11-19T22:54:10+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>FDA Updates Clinical Benefit List for Non-Malignant and Neurological Accelerated Approvals</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/630a5211-4774-4167-8685-91b046240fc2/a49ba69f-8eb0-4d34-a95a-ef6a9388da2d.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/abbvie-217-million-barceloneta-puerto-rico-biologics-campus-modernization</loc>
    <lastmod>2026-11-19T22:57:15+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>AbbVie Invests $217 Million to Modernize Barceloneta Biologics Campus</news:title>
      <news:keywords>AbbVie</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/630a5211-4774-4167-8685-91b046240fc2/e6d07652-02bb-45ad-96fe-f3a8108c84c4.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/valneva-sweden-cross-functional-gmp-culture-solna-vaccine-manufacturing</loc>
    <lastmod>2026-11-19T22:58:13+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Valneva Sweden Builds Cross-Functional GMP Culture</news:title>
      <news:keywords>Valneva</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/398ea04a-5c22-4568-a8a3-711ee49539af/6233069b-9120-4a69-9e28-12630184d34c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ichnos-glenmark-ind-submission-isb-2301-trispecific-oncology</loc>
    <lastmod>2026-11-19T22:59:25+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Ichnos Glenmark Submits IND for Trispecific ISB 2301</news:title>
      <news:keywords>Ichnos</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/e69f2d26-0cbe-4a02-979d-2e6026078c0c.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/igi-ind-filing-fda-multi-mechanism-solid-tumor-immunotherapy</loc>
    <lastmod>2026-11-19T23:04:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>IGI Files IND for Multi-Mechanism Solid Tumor Immunotherapy</news:title>
      <news:keywords>IGI</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/1ef65d98-a1f3-4d34-839d-a8fcaf37012f.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/biocon-eu-approval-pertuzumab-biosimilar-her2-positive-breast-cancer</loc>
    <lastmod>2026-11-19T23:06:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Biocon Gains EU Approval for Pertuzumab Biosimilar in Breast Cancer</news:title>
      <news:keywords>Biocon</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/73705e2c-8760-4118-9ea2-9e9ca8a06097.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/pfizer-secures-2-63-billion-car-t-deal-starna-therapeutics-autoimmune</loc>
    <lastmod>2026-11-19T23:02:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Pfizer Secures $2.63 Billion Deal with Starna Therapeutics for Autoimmune Disease</news:title>
      <news:keywords>Pfizer</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/168fdb4b-e1ab-4403-8b6b-639ab1be90da.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-bms-second-fda-ind-acceptance-celmod-molecular-glue-degrader</loc>
    <lastmod>2026-11-19T22:52:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Achieves IND Acceptance for CELMoD Molecular Glue Degrader</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/02fa5714-b6fe-4451-b649-907e1e675581/a4c402db-74c6-4a17-9d49-205029467aaa.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genzyme-fda-approval-infilbray-gaucher-disease-type-3-neurological</loc>
    <lastmod>2026-11-19T22:49:49+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-19T00:00:00+05:30</news:publication_date>
      <news:title>Genzyme Gains FDA Approval for Infilbray as First GD3 Neurological Treatment</news:title>
      <news:keywords>Genzyme</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4aec1a28-5bd8-4a07-b136-84165ef9c4af/37950e99-899d-477b-a2e7-1a7e2bafc343.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ektah-advances-nks3-obesity-drug-phase-iia-24-million-funding</loc>
    <lastmod>2026-11-19T12:01:47+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>EktaH Advances NKS-3 Obesity Drug into Phase IIa</news:title>
      <news:keywords>EktaH</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ektah-nks-3-obesity-drug-phase-iia-bpifrance-funding20261119120125.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/innate-pharma-iph4502-phase-1-data-ena-2026-adc-linker-stability</loc>
    <lastmod>2026-11-19T11:51:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Innate Pharma Reports Phase 1 Results for IPH4502 ADC</news:title>
      <news:keywords>Innate Pharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/innate-pharma-iph4502-phase-1-adc-linker-stability-ena-202620261119115010.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/merck-discontinues-bellwave-011-phase-3-nemtabrutinib-dmc-review</loc>
    <lastmod>2026-11-19T11:45:19+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib</news:title>
      <news:keywords>Merck</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/merck-nemtabrutinib-bellwave-011-phase-3-discontinuation20261119114404.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-launches-global-reliance-disclosure-program-nme-bla-january-2027</loc>
    <lastmod>2026-11-18T22:40:41+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/ddff00b4-40c4-4240-8eb5-9508141d5762/26a146c8-ae41-4860-8d15-5ca931d303eb.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-draft-guidance-bayesian-methodology-clinical-trials-drug-biologics</loc>
    <lastmod>2026-11-19T11:41:43+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Draft Guidance Sets Bayesian Methods for Drug Trials</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-bayesian-methodology-draft-guidance-clinical-trials-drugs-biologics20261119113704.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/nuvalent-fda-accelerated-approval-neladalkib-alk-positive-nsclc</loc>
    <lastmod>2026-11-19T11:28:44+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC</news:title>
      <news:keywords>Nuvalent</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/nuvalent-neladalkib-nelkarmi-fda-approval-alk-positive-nsclc20261119112824.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mandos-fda-approval-lembaz-infantile-onset-niemann-pick-disease-type-c</loc>
    <lastmod>2026-11-19T11:22:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC</news:title>
      <news:keywords>Mandos</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/mandos-lembaz-fda-approval-infantile-onset-niemann-pick-disease-type-c20261119112140.webp</image:loc>
    </image:image>
  </url>
</urlset>